Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
147 hedge funds and large institutions have $1.42B invested in Momenta Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 82 increasing their positions, 29 reducing their positions, and 25 closing their positions.
183% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 29
35% more capital invested
Capital invested by funds: $1.05B → $1.42B (+$371M)
2.57% more ownership
Funds ownership: 96.94% → 99.51% (+2.6%)
7% less funds holding
Funds holding: 158 → 147 (-11)
21% less call options, than puts
Call options by funds: $834K | Put options by funds: $1.05M
44% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.42M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.57M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$7.28M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$5.74M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3.86M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.72M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.69M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$2.5M |
MNTA Hedge Fund Activity: Q1 2019 in Review
147 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q1 2019, worth a combined $1.42B — up 35% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MNTA and 14 opened new positions — a net loss of 11 holders — while 29 trimmed existing stakes and 82 added.
The largest buyer was BlackRock, adding an estimated $17.8M. The largest seller was D.E. Shaw & Co, cutting an estimated $5.74M.
- 147 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q1 2019, down from 158 in Q4 2018.
- Funds reported $1.42B of Momenta Pharmaceuticals, Inc. stock for Q1 2019, up 35% quarter-over-quarter.
- 14 funds opened new Momenta Pharmaceuticals, Inc. positions in Q1 2019 and 25 closed out, a net change of -11 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q1 2019 was BlackRock, an estimated $17.8M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q1 2019 was D.E. Shaw & Co, an estimated $5.74M sold.
Based on aggregated 13F filings for Q1 2019.